After an independent data safety monitoring board has looked through preliminary data from Galecto's phase IIb study of idiopathic pulmonary fibrosis (IPF), the company has been forced to rearrange the trial on the basis of the monitoring board's recommendations, according to a press statement.
The recommendation states that Galecto should stop dosing the drug GB0139 in its highest dose, 10 mg, since an imbalance has been observed in the various patient groups in the study. Namely among the patients receiving the lowest dose, 3 mg, in combination with existing standard treatments for IPF and the drugs nintedanib and pirfenidone.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Zealand Pharma sells shares for over USD 100m
With a 5% discount, the biotech company managed to sell 4,975,000 of its own shares in a direct issuance.
Zealand Pharma CEO: Share sale arms us for partnership negotiations
After a study success with short bowel syndrome treatment candidate, the Danish biotech company raised funding by issuing shares, preparing the company’s CEO, Adam Steensberg, to enter dialogs with a number of potential partners.
Complete company divestment is not part of Zealand Pharma's strategy
After a Nordnet analyst brought up the possibility of the Danish company being an acquisition target for foreign firms, CEO Adam Steensberg has ruled out the notion of a full sale.
Three scientists share chemistry Nobel for cancer improvement technology breakthrough
Danish national Morten Meldal and two colleagues have been awarded the prestigious award for their research into click chemistry, which is used the development of cancer drugs.
Audientes builds on Q2 momentum, maintains guidance
The hearing aid company has sold self-fitting hearing aids for over DKK 2m (USD 266,700) during the third quarter that ended in September.
Quality Assurance & Regulatory Affairs Manager 
Sales Manager Denmark 
Orifarm Healthcare Product Development PMO Director 
KLIFO is looking for a Senior QA Specialist GMP for our Glostrup office 
Senior Director Translational Pharmacology 
Senior/lead consultant at Emendo Engineering 
Downstream Processing CMC Specialist 
Clinical Project Lead 
Drug Safety Associate 
Lab Manager 
Scientist Radiochemistry 
Chief Business Officer 
Experienced IT Business Solutions Manager for the Danish Medicines Agency